RxDoctor Payments DataLook up a doctor →

Humdum Durrani, MD

Hematology & Oncology · Fort Smith, ARNPI 1184861270

Payments from drug & device makers

$323,770in general payments, 2019–2025

Across 1,099 payments — averaging $294.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$136K
  • Exelixis Inc.$117K
  • Caris MPI, Inc.$23K
  • Johnson & Johnson$16K
  • Seagen Inc.$15K
  • AstraZeneca$1K
  • plus $15K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen68$135,529
Exelixis Inc.63$117,447
Caris MPI, Inc.4$23,215
Johnson & Johnson(2 entities)66$16,220
Seagen Inc.20$14,549
AstraZeneca(2 entities)71$1,226
Janssen Scientific Affairs, LLC1$1,170
Pfizer84$1,120
Merck69$1,057
Novartis66$989
AbbVie28$791
Daiichi Sankyo Inc.35$765
E.r. Squibb & Sons, L.L.C.48$658
Eisai Inc.27$502
Intuitive Surgical6$483
Sanofi26$473
Takeda Pharmaceuticals U.S.A., Inc.20$441
Lilly USA, LLC21$431
GSK26$420
Incyte Corporation17$400
Puma Biotechnology, Inc.22$350
Bristol Myers Squibb22$311
Gilead(2 entities)20$301
Regeneron Healthcare Solutions, Inc.14$299
Karyopharm Therapeutics Inc.8$293
Genentech USA, Inc.23$291
EMD Serono, Inc.16$268
Bayer16$267
Sumitomo Pharma America, Inc.12$245
Pharmacyclics LLC, An Abbvie Company12$237
Array Biopharma Inc16$227
Astellas Pharma US Inc9$226
Ipsen Biopharmaceuticals, Inc11$169
Boehringer Ingelheim7$168
Rigel Pharmaceuticals, Inc.9$149
Mirati Therapeutics, Inc.4$133
Novocure Inc.2$126
ADC Therapeutics America, Inc.8$126
Deciphera Pharmaceuticals Inc.6$117
Intera Oncology, Inc1$108
Myovant Sciences Inc.6$103
Clovis Oncology, Inc.7$91
Beigene USA, Inc.6$88
Foundation Medicine, Inc.6$87
Kyowa Kirin, Inc.6$86
Pharmaessentia USA Corporation5$86
AVEO Pharmaceuticals, Inc.5$84
Acrotech Biopharma Inc.4$66
Tersera Therapeutics LLC3$65
Global Blood Therapeutics, Inc.5$61
AMAG Pharmaceuticals, Inc.5$60
Dova Pharmaceuticals4$49
Dendreon Pharmaceuticals LLC3$49
Apellis Pharmaceuticals, Inc.2$46
Iovance Biotherapeutics, Inc.3$43
Alnylam Pharmaceuticals Inc.2$36
Geron Corporation2$34
Servier Pharmaceuticals LLC2$32
Beone Medicines USA, Inc.2$30
Pharmacosmos Therapeutics Inc.2$30

How this compares

$323,770 in reported general payments places this provider in the 85th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$147,336
Medicare patients
481
Services billed
2,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fort Smith

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →